1646682-14-5
1646682-14-5 結(jié)構(gòu)式
基本信息
(S)-2-(2-((3'-(1-amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid
Benzeneacetic acid, 2-[[3'-[(1S)-1-amino-2-hydroxyethyl][1,1'-biphenyl]-3-yl]methoxy]-
物理化學性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/05/22 | HY-128570 | FD-IN-1 | 1646682-14-5 | 1 mg | 1590元 |
| 2025/05/22 | HY-128570 | FD-IN-1 FD-IN-1 | 1646682-14-5 | 5mg | 3500元 |
| 2025/05/22 | HY-128570 | FD-IN-1 FD-IN-1 | 1646682-14-5 | 10mM * 1mLin DMSO | 3850元 |
常見問題列表
FD-IN-1 (Compound 12) exhibits functional inhibition of AP activation (IC 50 =0.26 μM) in vitro in a membrane attack complex (MAC) deposition assay using 50% human whole blood (WB).
FD-IN-1 (Compound 12) demonstrates systemic suppression of AP activation in a lipopolysaccharide-induced alternative complement pathway (AP) activation model as well as local ocular suppression in intravitreal injection-induced AP activation model in mice expressing human FD.
FD-IN-1 (Compound 12) exhibits high oral bioavailability (C57BL6 mice 83%, Beagle dogs 70%) following oral administration (mice and dogs 10 mg/kg).
FD-IN-1 (Compound 12) exhibits terminal elimination half-lives (C57BL6 mice 1.6 h and Beagle dogs 3.8 h) following intravenous administration (mice and dogs 1 mg/kg).
| Animal Model: | Human FD knock-in mice |
| Dosage: | 3 and 10 mg/kg |
| Administration: | Oral gavage |
| Result: | The AP pathway was fully inhibited for up to 10 h at the 10 mg/kg dose. |